Positions company to further leverage strength of platform and advance programs through multiple data readouts and clinical value inflection points Strengthens balance sheet with cash, cash.
Following merger with Adaptive Phage Therapeutics in March, combined company reports funding sufficient to support important data readouts for lead clinical programs in 2025 Company will host a.